Phytopharmaceuticals in India: A case for perpetual ‘New Drug’-style regulation over ASU-style liberalisation and counterproductive genericisation. Read more
Affordable ORS for all: Industry’s imperative to align with WHO’s vision and recent regulatory wake-up call Read more
Pharmexcil urges balance between compliance and commerce to safeguard India’s export momentum and ‘Pharmacy of the World’ status Read more